Trasylol Could Face Labeling Changes After Joint Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.